Join BOPA
Back to news articles

Kite and Gilead UK&I 2024 CAR-T Fellowship and Medical Grants Programme now open

By BOPA Committee on 20th May 2024

Kite and Gilead UK & Ireland CAR-T Fellowship and Medical Grants Programme

The Kite and Gilead UK and Ireland Fellowship and Medical Grants Programme (GFP) is a medical grants funding stream that supports innovative best practice projects and initiatives that aim to improve the lives of patients.

The 2024 CAR-T Fellowship and Medical Grants Programme is now open and will be accepting applications until 28th June. Applications are invited from healthcare and third sector organisations (e.g., charities) who are seeking funding for a project that aligns with the goals of the programme. The Programme is looking to support projects and initiatives (up to £50,000) which ultimately lead to an improvement in patient care. This can include, but is not limited to, activities such as:

  • Initiatives to facilitate improved efficiency in patient care and shared care pathways between referring and CAR-T treatment centres
  • Audits assessing patient profiles, disease outcomes and treatment patterns
  • Monitoring of patient-reported outcomes, quality of life measures or educational tools for patients and carers
  • New infrastructure/processes established for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment
  • Investigations into better detection and treatment of special patient populations and sub-types

Further information on the 2024 CAR-T Fellowship and Medical Grants Programme can be found on Gilead’s website.

Date of preparation: May 2024

Code: UK-UNB-5542.

 

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article